Enterprise Value

2.431B

Cash

363.3M

Avg Qtr Burn

N/A

Short % of Float

17.23%

Insider Ownership

11.61%

Institutional Own.

86.57%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Relacorilant + Nab-paclitaxel Details
Ovarian cancer, Cancer, Solid tumor/s

Phase 3

Data readout

Phase 3

Data readout

Miricorilant Details
Non-alcoholic steatohepatitis

Phase 2b

Initiation

Dazucorilant Details
Amyotrophic lateral sclerosis

Phase 2

Data readout

Miricorilant Details
Obesity, Antipsychotic-Induced Weight Gain

Phase 2

Update

Relacorilant (GR antagonist) + Enzalutamide Details
Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer

Phase 2

Initiation

Phase 1b

Data readout

Failed

Discontinued